Infliximab for acute exacerbations of ulcerative colitis

  • Technology appraisal guidance
  • TA163
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the Department of Public Health and Epidemiology University of Birmingham:

  • Bryan S et al. Infliximab for the treatment of acute exacerbations of ulcerative colitis, June 2008.

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Manufacturers, or sponsors, were also invited to make written submissions. Professional or specialist and patient or carer groups gave their expert views on infliximab for the treatment of acute exacerbations of ulcerative colitis by providing a written statement to the Committee. Manufacturers, or sponsors, and professional or specialist and patient or carer groups have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Schering Plough

Professional or specialist and patient or carer groups:

  • National Association for Colitis and Crohn's Disease (NACC)

  • Association of Coloproctology of Great Britain and Ireland

  • British Society of Gastroenterology

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

Other consultees

  • Department of Health

  • Medway PCT

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal)

  • British National Formulary

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Novartis Pharmaceuticals UK Ltd

  • West Midlands Health Technology Assessment Collaboration

  • National Collaborating Centre for Nursing and Supportive Care

The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on infliximab for the treatment of acute exacerbations of ulcerative colitis by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Jon Rhodes, nominated by Royal College of Physicians – clinical specialist.

  • Professor David Rampton, nominated by Royal College of Physicians – clinical specialist.

  • Richard Driscoll (Director), nominated by The National Association for Colitis and Crohn's Disease – patient expert.

  • Mr Stuart Berliner (Director), nominated by The National Association for Colitis and Crohn's Disease – patient expert.